Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.
The European Task Force for Neuronopathic Gaucher Disease (NGD) met in 2006 to review its 2001 guidelines. Fifty-five patients from five European countries were reviewed; 29 were male and 26 female. The majority of the patients were homozygous for the L444P mutation. All had been on enzyme replacement therapy (ERT). However, there was considerable variation in the dose of ERT, as well as an uneven distribution of risk factors. Thus, the oldest patients were on the lowest doses, and several had had a total splenectomy, while the youngest patients had a high proportion of compound heterozygosity and were on the highest doses, and very few had had a splenectomy. This heterogeneity rendered analysis very difficult. However, some observations were possible. The older patients appeared to remain relatively stable despite a low dose of ERT. In the younger patients, there was no clear effect of high-dose ERT. However, the period of follow-up was too short in many patients to draw valid conclusions. These data will be used to draw up revised guidelines.
Davies
E H
EH
Metabolic Unit, Great Ormond Street Children's Hospital NHS Trust, Great Ormond Street, London, WC1N 3JH, UK.
Erikson
A
A
Collin-Histed
T
T
Mengel
E
E
Tylki-Szymanska
A
A
Vellodi
A
A
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D057487:Enzyme Therapy; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy* / Q000235:genetics*; D005962:Glucosylceramidase / Q000235:genetics; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007361:Intelligence Tests; D008297:Male; D009422:Nervous System Diseases / Q000473:pathology; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D005962:Glucosylceramidase